North Run Capital, LP Maxcyte, Inc. Transaction History
North Run Capital, LP
- $43 Million
- Q4 2022
A detailed history of North Run Capital, LP transactions in Maxcyte, Inc. stock. As of the latest transaction made, North Run Capital, LP holds 451,960 shares of MXCT stock, worth $714,096. This represents 5.73% of its overall portfolio holdings.
Number of Shares
451,960
Previous 556,960
18.85%
Holding current value
$714,096
Previous $3.62 Million
31.85%
% of portfolio
5.73%
Previous 7.35%
Shares
2 transactions
Others Institutions Holding MXCT
# of Institutions
118Shares Held
71.8MCall Options Held
0Put Options Held
0-
Cadian Capital Management, LP New York, NY8.23MShares$13 Million0.78% of portfolio
-
Mirabella Financial Services LLP London, X08.2MShares$13 Million1.16% of portfolio
-
Black Rock Inc. New York, NY8.14MShares$12.9 Million0.0% of portfolio
-
Morgan Stanley New York, NY6.7MShares$10.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.59MShares$8.83 Million0.0% of portfolio
About MAXCYTE, INC.
- Ticker MXCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 101,724,000
- Market Cap $161M
- Description
- MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...